• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用转运蛋白敲低 Caco-2 细胞研究他汀类药物的体外外排。

Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs.

机构信息

Absorption Systems L.P., 436 Creamery Way, Suite 600, Exton, PA 19341-2556.

出版信息

Drug Metab Dispos. 2011 Jul;39(7):1196-202. doi: 10.1124/dmd.111.038075. Epub 2011 Mar 29.

DOI:10.1124/dmd.111.038075
PMID:21447733
Abstract

The objective of the present study was to determine the efflux transporters responsible for acid and lactone statin drug efflux using transporter knockdown Caco-2 cells. The bidirectional transport was determined in Caco-2 cell monolayers in which the expression of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), or multidrug resistance associated protein 2 (MRP2) was knocked down by transduction with lentivirus containing human transporter-targeted small hairpin RNAs (shRNAs). Cells transduced with lentivirus containing nontargeted shRNA served as the vector control. Atorvastatin, lovastatin, and rosuvastatin displayed extremely low apical-to-basolateral (A-to-B) transport, which made the P(app,A-B) values too unreliable to calculate the efflux ratio. Thus, transport comparisons were performed using the B-to-A permeability (P(app,B-A)) values. Presented in the order of vector control, P-gp, BCRP, and MRP2 knockdown Caco-2 cells, the P(app,B-A) values (×10(-6), cm/s) were 28.1 ± 1.3, 8.6 ± 2.9, 20.3 ± 1.8, and 21.5 ± 1.6 for atorvastatin; 96.1 ± 7.1, 25.3 ± 3.5, 57.3 ± 9.8, and 48.2 ± 2.3 for fluvastatin; and 14.1 ± 1.9, 4.6 ± 1.7, 5.8 ± 0.7, and 6.6 ± 1.8 for rosuvastatin, respectively. Lovastatin and simvastatin showed no efflux in the vector control or knockdown cell monolayers in either lactone or acid forms. Results indicate that atorvastatin, fluvastatin, and rosuvastatin were transported by P-gp, BCRP, and MRP2. On the other hand, neither the lactone nor the resulting acid of lovastatin and simvastatin was transported by P-gp, BCRP, or MRP2. The current study demonstrated that the transporter knockdown Caco-2 cells are useful tools for studying drug-transporter interactions and should help eliminate some of the ambiguity associated with the identification of drug-transporter interactions based on chemical inhibitors alone.

摘要

本研究的目的是确定负责酸性和内酯他汀类药物外排的外排转运体,方法是使用含有靶向人转运体的小发夹 RNA(shRNA)的慢病毒转导 Caco-2 细胞,敲低 P-糖蛋白(P-gp)、乳腺癌耐药蛋白(BCRP)或多药耐药相关蛋白 2(MRP2)的双向转运。用含有非靶向 shRNA 的慢病毒转导的细胞作为载体对照。阿托伐他汀、洛伐他汀和罗苏伐他汀显示出极低的顶端到基底(A 到 B)转运,使得 P(app,A-B) 值极不可靠,无法计算外排比。因此,使用 B 到 A 的通透性(P(app,B-A))值进行转运比较。按照载体对照、P-gp、BCRP 和 MRP2 敲低 Caco-2 细胞的顺序,阿托伐他汀的 P(app,B-A) 值(×10(-6),cm/s)分别为 28.1±1.3、8.6±2.9、20.3±1.8 和 21.5±1.6;氟伐他汀分别为 96.1±7.1、25.3±3.5、57.3±9.8 和 48.2±2.3;罗苏伐他汀分别为 14.1±1.9、4.6±1.7、5.8±0.7 和 6.6±1.8。洛伐他汀和辛伐他汀在载体对照或敲低细胞单层中均未以内酯或酸的形式表现出外排。结果表明,阿托伐他汀、氟伐他汀和罗苏伐他汀由 P-gp、BCRP 和 MRP2 转运。另一方面,洛伐他汀和辛伐他汀的内酯或酸均不由 P-gp、BCRP 或 MRP2 转运。本研究表明,转运体敲低 Caco-2 细胞是研究药物-转运体相互作用的有用工具,应有助于消除仅基于化学抑制剂鉴定药物-转运体相互作用所带来的一些模糊性。

相似文献

1
Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs.利用转运蛋白敲低 Caco-2 细胞研究他汀类药物的体外外排。
Drug Metab Dispos. 2011 Jul;39(7):1196-202. doi: 10.1124/dmd.111.038075. Epub 2011 Mar 29.
2
Comparative Hepatic and Intestinal Efflux Transport of Statins.他汀类药物的肝脏和肠道外排转运比较
Drug Metab Dispos. 2021 Sep;49(9):750-759. doi: 10.1124/dmd.121.000430. Epub 2021 Jun 23.
3
Silencing the breast cancer resistance protein expression and function in caco-2 cells using lentiviral vector-based short hairpin RNA.使用基于慢病毒载体的短发夹RNA沉默Caco-2细胞中乳腺癌耐药蛋白的表达和功能。
Drug Metab Dispos. 2009 Apr;37(4):737-44. doi: 10.1124/dmd.108.023309. Epub 2009 Jan 8.
4
Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂与ABCB1、ABCC2和OATP1B1的差异相互作用
Drug Metab Dispos. 2005 Apr;33(4):537-46. doi: 10.1124/dmd.104.002477. Epub 2004 Dec 22.
5
Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.阿托伐他汀在Caco-2细胞模型中的转运:P-糖蛋白和质子-单羧酸共转运体的作用
Pharm Res. 2000 Feb;17(2):209-15. doi: 10.1023/a:1007525616017.
6
Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.由多药耐药相关蛋白2(MRP2)和乳腺癌耐药蛋白(BCRP)介导的小肠外排作用将柳氮磺胺吡啶的肠道通透性从高转变为低,从而实现其结肠靶向性。
Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18.
7
Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.锌指核酸酶介导的基因敲除导致Caco-2细胞中P-糖蛋白、乳腺癌耐药蛋白(BCRP)和多药耐药相关蛋白2(MRP2)的转运活性丧失。
Drug Metab Dispos. 2015 Feb;43(2):199-207. doi: 10.1124/dmd.114.057216. Epub 2014 Nov 11.
8
Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.Caco-2 和 MDCK-MDR1 单层细胞中外排转运蛋白抑制剂的差异选择性:评估新化学实体与 P-糖蛋白、BCRP 和 MRP2 相互作用的策略。
J Pharm Sci. 2012 May;101(5):1888-97. doi: 10.1002/jps.23069. Epub 2012 Feb 22.
9
Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine.多种外排泵参与秋水仙碱的跨上皮转运:p-糖蛋白和多药耐药相关蛋白 2 的联合作用导致整个小肠的肠道吸收减少。
Drug Metab Dispos. 2009 Oct;37(10):2028-36. doi: 10.1124/dmd.109.028282. Epub 2009 Jul 9.
10
The Impact of Breast Cancer Resistance Protein (BCRP/ABCG2) on Drug Transport Across Caco-2 Cell Monolayers.乳腺癌耐药蛋白(BCRP/ABCG2)对 Caco-2 细胞单层跨膜药物转运的影响。
Drug Metab Dispos. 2020 Jun;48(6):491-498. doi: 10.1124/dmd.119.088674. Epub 2020 Mar 19.

引用本文的文献

1
Knockout Transporter Cell Lines to Assess Substrate Potential Towards Efflux Transporters.建立敲除转运体的细胞系以评估底物对外排转运体的潜在作用。
AAPS J. 2024 Jul 10;26(4):79. doi: 10.1208/s12248-024-00950-6.
2
Blood-brain barrier transporters: a translational consideration for CNS delivery of neurotherapeutics.血脑屏障转运体:神经治疗药物 CNS 递药的转化考量。
Expert Opin Drug Deliv. 2024 Jan-Jun;21(1):71-89. doi: 10.1080/17425247.2024.2306138. Epub 2024 Jan 31.
3
In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software.
基于 GastroPlus™ 软件的阿托伐他汀片剂生物等效性的计算机预测。
BMC Pharmacol Toxicol. 2023 Nov 28;24(1):69. doi: 10.1186/s40360-023-00689-4.
4
Mechanistic Static Model based Prediction of Transporter Substrate Drug-Drug Interactions Utilizing Atorvastatin and Rifampicin.基于机制静态模型的阿托伐他汀和利福平预测药物转运体底物药物相互作用。
Pharm Res. 2023 Dec;40(12):3025-3042. doi: 10.1007/s11095-023-03613-x. Epub 2023 Oct 11.
5
Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents.FDA 和 EMA 批准的丙型肝炎直接抗病毒药物介导的药代动力学药物相互作用的机制和临床意义。
Clin Pharmacokinet. 2023 Oct;62(10):1365-1392. doi: 10.1007/s40262-023-01302-x. Epub 2023 Sep 20.
6
Canine Intestinal Organoids as a Novel In Vitro Model of Intestinal Drug Permeability: A Proof-of-Concept Study.犬肠道类器官作为一种新型的肠道药物渗透体外模型:概念验证研究。
Cells. 2023 Apr 27;12(9):1269. doi: 10.3390/cells12091269.
7
Effects of Ethanolic Extract of on the Pharmacokinetics of Rosuvastatin in Rats.对大鼠体内瑞舒伐他汀药代动力学的影响。
Drug Des Devel Ther. 2022 May 17;16:1473-1481. doi: 10.2147/DDDT.S364234. eCollection 2022.
8
Regulation of Blood-Brain Barrier Transporters by Transforming Growth Factor-/Activin Receptor-Like Kinase 1 Signaling: Relevance to the Brain Disposition of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors (i.e., Statins).转化生长因子-/激活素受体样激酶 1 信号对血脑屏障转运体的调节:与 3-羟基-3-甲基戊二酰辅酶 A 还原酶抑制剂(即他汀类药物)在脑部分布的相关性。
Drug Metab Dispos. 2022 Jul;50(7):942-956. doi: 10.1124/dmd.121.000781. Epub 2022 May 3.
9
Case Study 7: Transporters Case Studies-In Vitro Solutions for Translatable Outcomes.案例研究 7:转运蛋白案例研究-可转化结果的体外解决方案。
Methods Mol Biol. 2021;2342:709-735. doi: 10.1007/978-1-0716-1554-6_26.
10
The Role of Structure and Biophysical Properties in the Pleiotropic Effects of Statins.他汀类药物多效性的结构和生物物理特性作用。
Int J Mol Sci. 2020 Nov 19;21(22):8745. doi: 10.3390/ijms21228745.